logo
What is vitamin B6 toxicity and what are the symptoms of taking too much?

What is vitamin B6 toxicity and what are the symptoms of taking too much?

The Guardian2 days ago
In January Guardian Australia told the story of Simon Bogemann who developed a nerve condition known as peripheral neuropathy after consuming excessive vitamin B6 from multivitamin and magnesium supplements.
Since then, the potential of these over-the-counter supplements to cause harm has attracted increasing attention.
An interim decision from the Therapeutic Goods Administration proposes changes that could see products containing more than 50mg of vitamin B6 become pharmacist-only medicines.
A potential class action against Blackmores is also being considered for excessive B6 levels in the company's vitamin supplements.
As the regulator considers further action, here's what you need to know about vitamin B6.
Vitamin B6 toxicity occurs when people consume excessive amounts of B6-containing supplements and have levels in their blood higher than what the body needs.
Dr Terri-Lynne South, a GP, dietician and spokesperson for the Royal College of General Practitioners, says: 'Back in the day, B6 was what we would call a water-soluble vitamin, and the wisdom was you can't overdose on water-soluble vitamins … But we found, certainly with B6, that's not the case, that it is stored in the body.'
Higher than normal amounts of B6 stored in the blood can have damaging effects, South says, 'particularly to some of our peripheral nerves – nerves in the extremities'. It can cause dysfunction, including pain, pins and needles, loss of sensation and loss of motor function in extreme cases.
Vitamin B6 is found naturally in many foods including fish, non-citrus fruits and starchy vegetables. High intake of B6 from natural sources have not been reported to cause adverse effects.
Sign up: AU Breaking News email
B6 is also found in many supplements, including magnesium, multivitamins, zinc, and B-complex formulas, as well as fortified foods, including energy drinks, breakfast cereals and weight loss shakes. B6 toxicity occurs when people consume excessive amounts of B6 from these non-natural sources.
People only need about 1mg of B6, so it can be very easy to consume too much, South says. 'Part of the problem is that B6 is known by different names [including] pyridoxine, pyridoxal, and so it can be difficult for people to actually know how much B6 they're getting from all sources.'
People should be mindful if they are taking vitamin or mineral supplements, or using products with B6 such as energy drinks. The symptoms of B6 toxicity which lead to peripheral neuropathy are not very specific, meaning they could have many causes, South says. If people have pins and needles in the hands and feet, or a burning sensation, numbness or difficulty with balance or walking, 'I wouldn't necessarily jump to say that it's B6 toxicity.'
Be aware of the many sources B6 is found in, as well as its numerous names including pyridoxine, pyridoxal or pyridoxamine, South says. 'Work out how much you might be having a day,' South says. If it's greater than 50mg, South recommends talking to a GP or pharmacist about your consumption.
Even if people don't have symptoms, they should not be taking more than 50mg a day, she says. There is still some conjecture about whether amounts even lower than 50mg can cause toxicity. 'It is very individual at what point in time someone who's having excessive sources of B6 may get symptoms of toxicity,' South says.
If people do experience symptoms, a blood test could help work out whether it is B6 toxicity or something else, she says.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Erin is a gentle and beloved single mum in Melbourne. She's just been diagnosed with Alzheimer's at 29
Erin is a gentle and beloved single mum in Melbourne. She's just been diagnosed with Alzheimer's at 29

Daily Mail​

time5 hours ago

  • Daily Mail​

Erin is a gentle and beloved single mum in Melbourne. She's just been diagnosed with Alzheimer's at 29

At just 29, Melbourne mum Erin Kelly is facing the heartbreaking reality that she's living on borrowed time. A single parent to her eight-year-old daughter Evie, Erin has recently been diagnosed with early onset Alzheimer's - a devastating blow made even more cruel by its rare genetic cause. Now she's in a race against the clock to fund the one treatment that could slow it down. 'There's no chance of me reaching retirement age so I'm doing everything I can now, while I still can,' Erin told the Daily Mail. Alzheimer's typically strikes later in life, but for Erin, it's deeply personal, and terrifyingly genetic. In May 2024, the young mum discovered she carries a rare mutation of the PSEN1 gene, one that guarantees she will develop Alzheimer's earlier than normal. Only about 200 families worldwide carry it. 'With young onset Alzheimer's, they (the specialists) said only 1 per cent of young onset Alzheimer's cases are caused by a genetic mutation,' Erin said. 'I always knew there was a 50/50 chance I'd develop it later in life. But even with my family history, I never imagined it would happen to me this early.' Erin lost her mum to Alzheimer's when she was just 17. Her mum was only 50. After further digging, she's now found out that eight members of her extended family have battled the disease too. However, the PSEN1 mutation is what makes Erin's diagnosis so rare and so aggressive. Doctors can't say much without more tests, but have told Erin that her life expectacny is between another eight to 15 years. The official diagnosis came in July, following a year-long journey of MRIs, specialist consultations and anxious waiting. It was Erin's father who first urged her to get tested for the mutation in May 2024, after she began noticing small lapses and mixed-up words, which she initially dismissed. 'A year ago I contacted Alzheimer's Australia, but they originally said they couldn't help because I didn't have a confirmed diagnosis yet,' she said. 'So, I reached out to many others including neurologists, and they all said they didn't really know what to do with me. But then I ended up with a geriatrician [a doctor specialising in the care of the elderly], and he is helping.' Despite early symptoms and a clear family history, getting answers has been slow and costly. Specialists charged up to $500 a visit. Each scan costs her hundreds more. She has since been referred to a neuropsychologist, speech therapist and dietitian - but couldn't afford to see any of them. Even a medical drink called Souvenaid, formulated to support memory in Alzheimer's patients, was too expensive at $100 a month. 'I've had to pick and choose what I can pay for. I just can't justify that as well, given the position we're in,' she said. Despite her diagnosis, Erin was told she is too young to qualify for Australian clinical trials or subsidised treatment. 'It's like they don't know what to do with me,' she said. But there is a treatment that could help, which is a breakthrough infusion drug called Leqembi. Leqembi, which is administered as an infusion every two weeks, has been shown to slow the progression of Alzheimer's by up to 30 per cent. It works by targeting and removing the sticky amyloid plaques that kill brain cells and cause cognitive decline. There's just one problem - it's only available on a case-by-case basis for people aged 50 to 90, and at a staggering cost of $90,000. 'My doctor basically said that I don't cover a lot of the criteria. But if I can supply the money, then I've got a much higher chance of being accepted,' she said. Since Evie was six weeks old, it's been just the two of them. Erin has poured every ounce of her energy into raising her daughter and building a stable life. Now, she's fighting to hold onto that life and the precious time she has left. She's started creating photo books and writing letters for Evie, capturing memories and family stories she fears she won't be able to tell one day. 'I want her to remember who I was. Who her grandmother was, too, as I'm the only one who can tell her that,' she said. A breakthrough infusion drug called Leqembi could delay Erin's symptoms by up to 30 per cent, but she is too young to qualify for it - unless she can pay $90,000 Erin's family hopes to raise the full $90,000 to cover ongoing treatments and give her a fighting chance at slowing the disease in its tracks. If treatment becomes impossible, the funds will help create lasting memories with Evie too, as well as special time together, and the chance to simply live while she still can. 'She's not asking for a miracle,' her stepsister Jessica said. 'She's just asking for more time.'

Sorry America, but it's not Australia's fault that your healthcare system is failing you
Sorry America, but it's not Australia's fault that your healthcare system is failing you

The Guardian

time11 hours ago

  • The Guardian

Sorry America, but it's not Australia's fault that your healthcare system is failing you

If I were president of the United States, I would certainly be concerned about the cost and performance of the country's healthcare system. The grim statistics are well known. As of 2022, the US spent $12,555 per person on healthcare, almost twice as much as other wealthy countries, including Australia. That gap alone cancels out about half of the difference in income per person between the US and Australia, according to World Bank estimates. Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries. This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes. Sign up: AU Breaking News email And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic. There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse. It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US. The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists. And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US. This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe. More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector. But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory. The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange. John Quiggin is a professor at the University of Queensland's school of economics

Sorry America, but it's not Australia's fault that your healthcare system is failing you
Sorry America, but it's not Australia's fault that your healthcare system is failing you

The Guardian

time17 hours ago

  • The Guardian

Sorry America, but it's not Australia's fault that your healthcare system is failing you

If I were president of the United States, I would certainly be concerned about the cost and performance of the country's healthcare system. The grim statistics are well known. As of 2022, the US spent $12,555 per person on healthcare, almost twice as much as other wealthy countries, including Australia. That gap alone cancels out about half of the difference in income per person between the US and Australia, according to World Bank estimates. Higher expenditure on healthcare would not be a problem if it delivered a healthier population. But this is not the case. The US has one of the lowest life expectancies of any rich country. And even though more Americans die young, those who survive have worse health than elsewhere. Americans suffer from chronic diseases like diabetes, asthma and depression at around twice the (age-adjusted) rate of other rich countries. This gap is too large to be accounted for by specific causes like gun violence or drug overdoses, or even unequal income distribution. The US has worse health outcomes at every point on the income distribution scale than other rich countries, even though those at the upper end have much higher incomes. Sign up: AU Breaking News email And the problem is getting worse. The US saw declining life expectancy in the years after 2014 and, unlike other countries, saw a late, limited recovery from the increased death rate after the onset of the Covid pandemic. There's not much hope for rapid progress in US health outcomes. The destruction of US public health infrastructure through budget cuts, the gutting of key agencies such as the Center for Disease Control and the appointment of notorious anti-vaxxer RFK Jr as secretary of health and human services will only make matters worse. It's unsurprising then that President Donald Trump is looking at the cost side of the equation. As might be expected he has raised, again, the perennial grievances of US health policy. This is the fact that Americans pay far more for prescription medicines than do citizens of other countries where prices are controlled through mechanisms like Australia's Pharmaceutical Benefits Scheme (PBS). And, given his grievance-based approach to the world in general, it is no surprise that his latest statement on the topic describes Australia and other countries as 'freeloaders' on the US. The US government is, of course, entirely within its rights to set its own policy regarding the pricing of prescription drugs. The US Department of Veterans Affairs already has a program similar to the PBS, under which it pays about half as much of the typical US price. There is no reason this couldn't be extended to the entire US Medicare system, except that the result would be to close down 1,000 or more private plans, each with their own lobbyists. And with a bit more effort, the US could establish its own version of the PBS, covering all Americans. Quite possibly, faced with lower prices in the US, pharmaceutical companies might demand higher returns from other countries including Australia. But a systematic reform of this kind is beyond the capacity of the Trump administration. Instead we have seen the typical Trumpian claim that other countries are benefiting unfairly from medical research done in the US. This was arguably true in the second half of the 20th century when the US was the undoubted centre of global medical research, most notably through the National Institutes of Health. But funding for the NIH (adjusted for inflation) peaked in 2004, and has suffered from decades of financial stringency. Meanwhile, the US share of genuine innovations, measured by 'new molecular entities' has declined and is no longer notably larger (relative to GDP) than that of leading European innovators. The development of semaglutide (Ozempic and Wegovy) treatments for obesity and diabetes by Danish firm Novo Nordisk is a notable example of a drug of particular importance to the US being developed in Europe. More generally, if Trump wants to import ideas like the PBS into the US system, Australia has plenty to offer. Australia's Medicare system, combining a single-payer universal scheme for standard healthcare with private insurance and fee-for-service medicine as an upper tier, could provide a politically palatable way of delivering the US demand for 'Medicare for all' without destroying the private sector. But of course, this isn't the Trump way. What we will doubtless see, as in the recent tariff negotiations, is a series of bullying demands, resulting in triumphant announcements of magnificent deals, which turn out, on closer inspection, to be largely illusory. The bigger lesson for Australia in all of this is that, as with China, we need to treat the US not as an ally or friend but as a trading partner which will seek to push us around whenever possible. The correct response, again as with China, is to stand our ground until the other side sees the pointlessness of bullying and the mutual benefits of free exchange. John Quiggin is a professor at the University of Queensland's school of economics

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store